Search
All Clinical Trials in Canada
A listing of 3904 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
493 - 504 of 3904
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +221 locations
University of Alabama at Birmingham, Birmingham, Alabama
Local Institution - 0229, Phoenix, Arizona
Local Institution - 0230, Phoenix, Arizona
The University of Arizona Arthritis Center, Tucson, Arizona
Kaiser Permanente, Fontana, California
Private Practice - Dr. Chandrakant V. Mehta, Hemet, California
Local Institution - 0247, La Mesa, California
Arthritis & Osteoporosis Medical Center - La Palma, La Palma, California
UCLA Clinical & Translational Research Center (CTRC), Los Angeles, California
Local Institution - 0248, Sacramento, California
Local Institution - 0253, San Diego, California
Local Institution - 0128, Santa Barbara, California
Local Institution - 0099, Denver, Colorado
Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut
Rheumatology Assoc. Of South Florida, Boca Raton, Florida
Local Institution - 0249, Coral Springs, Florida
Nouvelle Clinical Research, Cutler Bay, Florida
University of Florida College of Medicine, Gainesville, Florida
University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida
Omega Research Group - Orlando, Orlando, Florida
Discovery Health Research, Plantation, Florida
West Broward Rheumatology Associates, Tamarac, Florida
Genesis Clinical Research, LLC, Tampa, Florida
Local Institution - 0165, Tampa, Florida
Piedmont West, Atlanta, Georgia
Local Institution - 0228, Lawrenceville, Georgia
Local Institution - 0234, Lawrenceville, Georgia
North Georgia Rheumatology, Lawrenceville, Georgia
IBJI Morton Grove, Morton Grove, Illinois
Greater Chicago Specialty Physicians, Schaumburg, Illinois
Local Institution - 0108, Indianapolis, Indiana
Lake Cumberland Rheumatology, New Albany, Indiana
Ochsner Clinic Foundation, New Orleans, Louisiana
Local Institution - 0006, Detroit, Michigan
Saint Paul Rheumatology, Eagan, Minnesota
Atlantic Health System Overlook Medical Center, Summit, New Jersey
Local Institution - 0159, Bronx, New York
The Feinstein Institute for Medical Research, Manhasset, New York
NYU Langone Health, New York, New York
University of Rochester Medical Center, Rochester, New York
Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina
Carolinas HealthCare System SouthPark, Charlotte, North Carolina
Local Institution - 0246, Summerville, South Carolina
Local Institution - 0003, Memphis, Tennessee
Arthritis and Rheumatology Research Institute, Allen, Texas
UT Southwestern Medical Center, Dallas, Texas
Local Institution - 0088, Fort Worth, Texas
Local Institution - 0250, Houston, Texas
Local Institution - 0219, Lubbock, Texas
Advanced Rheumatology of Houston - Woodlands, The Woodlands, Texas
Carilion Clinic, Roanoke, Virginia
Swedish Medical Center, Seattle, Washington
Local Institution - 0139, Seattle, Washington
Local Institution - 0063, Franklin, Wisconsin
Instituto De Investigaciones Clinicas Quilmes, Quilmes, Buenos Aires
Fundacion Cidea, Buenos Aires, Ciudad Autónoma De Buenos Aires
APRILLUS Asistencia e Investigacion Clinica, Caba, Ciudad Autónoma De Buenos Aires
Investigaciones Clínicas Tucumán, San Miguel de Tucuman, Tucumán
Private Practice - Dr. Javier Gerardo Tartaglione, Buenos Aires, Not set
Hospital Británico de Buenos Aires, Buenos Aires, Not set
Stat Research S.A., Ciudad Autónoma de Buenos Aires, Not set
Hospital J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Not set
Hospital Córdoba, Córdoba, Not set
Instituto de Reumatología, Mendoza, Not set
Serviços Especializados em Reumatologia, Salvador, Bahia
Hospital Brasilia, Lago sul, Distrito Federal
Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Minas Gerais
Cmip-Centro Mineiro de Pesquisa, Juiz de Fora, Minas Gerais
Hospital Universitário Evangélico Mackenzie, Curitiba, Paraná
Local Institution - 0075, Niteroi, Rio De Janeiro
Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul
Clinica Medica Bonfiglioli, Campinas, São Paulo
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) - HCFMRP, Ribeirão Preto, São Paulo
Hospital do Rim e Hipertensão, Sao Paulo, São Paulo
Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo
Hospital Universitário Pedro Ernesto, Rio de Janeiro, Not set
Hospital das Clinicas FMUSP, São Paulo, Not set
Local Institution - 0048, São Paulo, Not set
Medical Center Artmed, Plovdiv, Not set
MC Excelsior, Sofia, Not set
ACIBADEM City Clinic Diagnostic-Consultative Center, Sofia, Not set
University of Calgary, Cumming School of Medicine, Calgary, Alberta
Local Institution - 0160, Hamilton, Ontario
St. Joseph's Health Care, London, Ontario
Toronto Western Hospital, Toronto, Ontario
Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski, Rimouski, Quebec
The First Afflilated Hospital of Bengbu Medical College, Bengbu, Anhui
Beijing Peking Union Medical College Hospital, Beijing, Beijing
The First Affiliated hospital of Xiamen University, Xiamen, Fujian
Guangdong Provincial People's Hospital, Guangzhou, Guangdong
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong
ShenZhen People's Hospital, Shenzhen, Guangdong
Local Institution - 0153, Baoding, Hebei
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang, Henan
The First Affiliated Hospital of Zhengzhou Universtiy, Zhengzhou, Henan
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei
Xiangya Hospital Central South University, Changsha, Hunan
ZhuZhou Central Hospital, Zhuzhou, Hunan
Local Institution - 0059, Baotou, Inner Mongolia
The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia
The First People's Hospital of Changzhou, Changzhou, Jiangsu
Jiu Jiang No.1 People's Hospital, Jiujiang, Jiangxi
Local Institution - 0071, Nanchang, Jiangxi
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi
Pingxiang People's Hospital, Pingxiang, Jiangxi
The First Hospital of China Medical University, Shenyang, Liaoning
Shengjing Hospital of China Medical University, Shenyang, Liaoning
Local Institution - 0149, Jinan, Shandong
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai
Huashan Hospital, Fudan University, Shanghai, Shanghai
Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai
West China Hospital, Sichuan University, Cheng Du, Sichuan
Local Institution - 0053, Tianjin, Tianjin
People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang
The first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang
Wenzhou People's Hospital, Wenzhou, Zhejiang
Shanxi Bethune Hospital, Taiyuan, Not set
Salud SURA Industriales, Medellín, Antioquia
Centro Integral de Reumatología del Caribe, Barranquilla, Atlántico
Servimed EU, Bucaramanga, Santander
Hospital Universitario San Ignacio, Bogota, Not set
Cireem Sas, Bogotá, Not set
IPS Centro Médico Julián Coronel S.A.S, Cali, Not set
Local Institution - 0058, Cali, Not set
Preventive Care, Chia, Not set
Local Institution - 0055, Medellin, Not set
Nouvel Hôpital Civil (NHC), Strasbourg, Alsace
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes, Loire-Atlantique
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin-Bicêtre, Not set
Local Institution - 0156, Tours, Not set
Universitaetsklinikum Tuebingen, Tübingen, Baden-Württemberg
Klinikum der Ludwig-Maximilians-Universitaet Muenchen, Muenchen, Bayern
Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen
Universitätsklinikum Schleswig-Holstein, Lübeck, Schleswig-Holstein
DRK-Krankenhaus Rabenstein, Chemnitz, Not set
Universitaetsklinikum Erlangen, Erlangen, Not set
Universitaetsklinikum Koeln, Köln, Not set
Klinische Forschung im medizinischen Versorgungalltag GbR, Planegg, Not set
Tuen Mun Hospital, Tuen Mun, Not set
Local Institution - 0213, Vizianagaram, Andhra Pradesh
Amber Clinic, Ahmedabad, Gujarat
Local Institution - 0243, Surat, Gujarat
Medanta The Medicity, Gurugram, Haryana
ChanRe Rheumatology And Immunology Center And Research, Bengaluru, Karnataka
ESIC Medical College, Hyderabad, Telangana
Nizam's Institute of Medical Sciences, Hyderabad, Telangana
Local Institution - 0119, Manorhamilton, Leitrim
Local Institution - 0130, Cork, Not set
Local Institution - 0157, Dublin, Not set
Local Institution - 0172, Dublin, Not set
AOU Policlinico Umberto I, Roma, Lazio
Centro Specialistico Ortopedico Traumatologico Gaetano Pini - CTO, Milano, Lombardia
Azienda Ospedaliera Universitaria Pisana, Pisa, Toscana
Azienda Ospedale - Università Padova, Padova, Veneto
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Not set
Ospedale San Raffaele, Milano, Not set
AOU della Campania Luigi Vanvitelli, Napoli, Not set
Local Institution - 0118, Pavia, Not set
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma, Verona, Not set
Chonnam National University Hospital, Gwangju-si, Kwangju-Kwangyǒkshi
Ajou University Hospital, Suwon, Kyǒnggi-do
The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [Seoul]
Local Institution - 0105, Jung-gu, Taegu-Kwangyǒkshi
Local Institution - 0106, Jung-gu, Taejǒn-Kwangyǒkshi
Hanyang University Seoul Hospital, Seoul, Not set
Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas, Kauno Apskritis
Centro Medico del Angel, Mexicali, Baja California
Boca Clinical Trials Mexico SC, Ciudad de México, Distrito Federal
Local Institution - 0027, Mexico City, Distrito Federal
Instituto para el DeSarrollo Integral de la Salud S de RL de CV, Mexico City, Distrito Federal
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal
Clinstile, S.A. de C.V., Mexico, Distrito Federal
Hospital Aranda de La Parra, Leon, Guanajuato
Local Institution - 0024, Zapopan, Jalisco
Investigacion y Biomedicina de Chihuahua, Chihuahua, Not set
Local Institution - 0014, Mexico City, Not set
Boca Clinical Trials Mexico SC, Puebla, Not set
Local Institution - 0237, Chisinau, Chișinău
Local Institution - 0238, Chisinau, Chișinău
Republican Clinical Hospital, Chisinau, Not set
Hogar Clínica San Juan de Dios, Arequipa, Not set
Instituto Peruano del Hueso y la Articulación, Lima, Not set
Centro Medico CORPAC, Lima, Not set
Investigaciones Clínicas / Instituto de Ginecología y Reproducción, Lima, Not set
Local Institution - 0196, Wroclaw, Dolnośląskie
Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy, Bydgoszcz, Kujawsko-pomorskie
Local Institution - 0244, Lublin, Lubelskie
Mak-Med Clinic Sp. Z O.O., Nadarzyn, Mazowieckie
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji, Warsaw, Mazowieckie
Rheuma Medicus Sp. z o.o., Warszawa, Mazowieckie
Local Institution - 0194, Wolomin, Mazowieckie
Centrum Medyczne Plejady, Krakow, Małopolskie
Medyczne Centrum Hetmańska, Poznan, Wielkopolskie
Local Institution - 0030, Poznań, Wielkopolskie
Nova Reuma Społka Partnerska, Bialystok, Not set
Synexus Polska Sp. z o.o. Oddzial w Poznaniu, Poznan, Not set
Local Institution - 0211, Belchatow, Łódzkie
Centrum Medyczne Pratia Katowice, Katowice, Śląskie
Local Institution - 0073, Lisbon, Not set
Centro Reumatologico Caguas, Caguas, Not set
Local Institution - 0252, San Juan, Not set
GCM Medical Group, PSC - Hato Rey Site, San Juan, Not set
Hiperdia Piața Sudului, Bucharest, Bucureşti
Hightech Medical Services SRL-Centrul pentru Studiul Metabolismului, Bucharest, București
Spital Clinic Sf. Maria, Bucharest, București
Delta Health Care, Bucharest, București
Spitalul Clinic Colentina, Bucuresti, București
CCBR Clinical Research, Bucuresti, București
Medisof Diagnostic SR, Craiova, Dolj
RK Medcenter, Iasi, Iași
Sc Medaudio-Optica Srl, Râmnicu Vâlcea, Vâlcea
Private Practice - Dr. Carina Anna Triff, Timisoara, Not set
Local Institution - 0207, Svidnik, Prešovský Kraj
Local Institution - 0206, Martin, Žilinský Kraj
Local Institution - 0232, Pretoria, GP
Local Institution - 0233, Cape Town, Western Cape
Local Institution - 0231, Stellenbosch, Western Cape
Gazi University Health Research and Application Center Gazi Hospital, Ankara, Not set
Istanbul University Cerrahpasa Medical School Internal Diseases Institute, Istanbul, Not set
Kocaeli Üniversitesi, Kocaeli, Not set
Conditions: Systemic Lupus Erythematosus
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Recruiting
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).
The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD.
The study duration per participant will be up to 180 weeks, including:
* A screening period of up to 2 to 4 weeks
* An open label treatment period of up to 160 weeks (approximately 3 years)
* A po... Read More
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD).
The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD.
The study duration per participant will be up to 180 weeks, including:
* A screening period of up to 2 to 4 weeks
* An open label treatment period of up to 160 weeks (approximately 3 years)
* A post-treatment safety follow-up period of at least 20 weeks after the last dose administration
The planned number of visits will be 26 visits. Read Less
Gender:
ALL
Ages:
12 years and above
Trial Updated:
08/07/2025
Locations: Alabama Allergy & Asthma Center - Birmingham - Brookwood Boulevard- Site Number : 8400050, Birmingham, Alabama +189 locations
Alabama Allergy & Asthma Center - Birmingham - Brookwood Boulevard- Site Number : 8400050, Birmingham, Alabama
Research Solutions of Arizona- Site Number : 8400020, Litchfield Park, Arizona
Medical Dermatology Specialists- Site Number : 8400016, Phoenix, Arizona
Dermatology Trial Associates- Site Number : 8400027, Bryant, Arkansas
University Dermatology Trials, INC.- Site Number : 8400052, Newport Beach, California
Children's Hospital Colorado - Aurora- Site Number : 8400041, Aurora, Colorado
IMMUNOe International Research Centers - Centennial- Site Number : 8400024, Centennial, Colorado
Renaissance Research and Medical Group- Site Number : 8400006, Cape Coral, Florida
Life Clinical Trials - Coral Springs- Site Number : 8400040, Coral Springs, Florida
Florida Pharmaceutical Research and Associates- Site Number : 8400018, Miami, Florida
Bio-Medical Research- Site Number : 8400037, Miami, Florida
Miami Clinical Research Tower- Site Number : 8400036, Miami, Florida
Florida Research Center, Inc.- Site Number : 8400011, Miami, Florida
Clinical Research Trials of Florida- Site Number : 8400054, Tampa, Florida
Advanced Medical Research - Atlanta- Site Number : 8400044, Atlanta, Georgia
Georgia Skin & Cancer Clinic- Site Number : 8400048, Savannah, Georgia
Sneeze Wheeze And Itch Assoc- Site Number : 8400002, Normal, Illinois
Velocity Clinical Research - Sioux City- Site Number : 8400046, Sioux City, Iowa
Kentucky Advanced Medical Research- Site Number : 8400014, Murray, Kentucky
Velocity Clinical Research - Baton Rouge- Site Number : 8400005, Baton Rouge, Louisiana
Oakland Hills Dermatology- Site Number : 8400021, Auburn Hills, Michigan
The Derm Institute of West Michigan- Site Number : 8400043, Caledonia, Michigan
Michigan Dermatology Institute - Livonia- Site Number : 8401010, Livonia, Michigan
Somerset Skin Centre- Site Number : 8400038, Troy, Michigan
Grekin Skin Institute - Warren- Site Number : 8400042, Warren, Michigan
Michigan Dermatology Institute - Waterford- Site Number : 8400010, Waterford, Michigan
Forest Hills Dermatology Group @ Union Turnpike- Site Number : 8400007, Kew Gardens, New York
Aesthetic Dermatology - Woodbury- Site Number : 8400031, Woodbury, New York
Unity Clinical Research- Site Number : 8400001, Oklahoma City, Oklahoma
Dermatology Research Center of Oklahoma, PLLC - Site Number : 8400035, Tulsa, Oklahoma
The Children's Hospital of Philadelphia- Site Number : 8400009, Philadelphia, Pennsylvania
Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400053, San Antonio, Texas
Pioneer Research Solutions - Sugar Land- Site Number : 8400026, Sugar Land, Texas
Private Practice - Dr. Marthe N. Dika- Site Number : 8400022, Burlington, Wisconsin
Investigational Site Number : 0320022, General Pico, La Pampa
Investigational Site Number : 0320006, Rosario, Santa Fe
Investigational Site Number : 0320007, Rosario, Santa Fe
Investigational Site Number : 0320008, Buenos Aires, Not set
Investigational Site Number : 0320001, Buenos Aires, Not set
Investigational Site Number : 0320003, Buenos Aires, Not set
Investigational Site Number : 0320002, Buenos Aires, Not set
Investigational Site Number : 0320004, Buenos Aires, Not set
Investigational Site Number : 0320009, Buenos Aires, Not set
Investigational Site Number : 0320005, Buenos Aires, Not set
Investigational Site Number : 0360002, Kogarah, New South Wales
Investigational Site Number : 0360001, Sydney, New South Wales
Centro de Pesquisas da Clínica IBIS- Site Number : 0760002, Salvador, Bahia
HC - UFPR - Hospital de Clínicas da Universidade Federal do Paraná- Site Number : 0760022, Curitiba, Paraná
Pontifica Universidade Catolica do Parana- Site Number : 0760023, Curitiba, Paraná
Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005, Porto Alegre, Rio Grande Do Sul
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760008, Ribeirão Preto, São Paulo
Faculdade de Medicina do ABC- Site Number : 0760001, Santo André, São Paulo
Clinica de Alergia Martti Antila- Site Number : 0760006, Sorocaba, São Paulo
Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760003, São José Do Rio Preto, São Paulo
IDERJ - Instituto de Dermatologia e Estética do Brasil- Site Number : 0760004, Rio de Janeiro, Not set
Investigational Site Number : 1240001, Calgary, Alberta
Investigational Site Number : 1240052, Edmonton, Alberta
Investigational Site Number : 1240051, Vancouver, British Columbia
Investigational Site Number : 1240009, Etobicoke, Ontario
Investigational Site Number : 1240008, Mississauga, Ontario
Investigational Site Number : 1240011, Oakville, Ontario
Investigational Site Number : 1240004, Peterborough, Ontario
Investigational Site Number : 1240003, Richmond Hill, Ontario
Investigational Site Number : 1240012, Toronto, Ontario
Investigational Site Number : 1240002, Montreal, Quebec
Investigational Site Number : 1240010, Québec City, Quebec
Investigational Site Number : 1240006, Québec City, Quebec
Investigational Site Number : 1240044, Saskatoon, Saskatchewan
Investigational Site Number : 1520009, Osorno, Los Lagos
Investigational Site Number : 1520004, Valdivia, Los Ríos
Investigational Site Number : 1520011, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520008, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520002, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520003, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520013, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520010, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520005, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520001, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520014, Chillán, Not set
Investigational Site Number : 1560015, Beijing, Not set
Investigational Site Number : 1560008, Changchun, Not set
Investigational Site Number : 1560016, Changsha, Not set
Investigational Site Number : 1560014, Chengdu, Not set
Investigational Site Number : 1560072, Fuzhou, Not set
Investigational Site Number : 1560074, Guangzhou, Not set
Investigational Site Number : 1560044, Hangzhou, Not set
Investigational Site Number : 1560011, Hangzhou, Not set
Investigational Site Number : 1560013, Jingzhou, Not set
Investigational Site Number : 1560001, Shanghai, Not set
Investigational Site Number : 1560018, Suzhou, Not set
Investigational Site Number : 1560010, Taiyuan, Not set
Investigational Site Number : 1560073, Taizhou, Not set
Investigational Site Number : 1560019, Xinxiang, Not set
Investigational Site Number : 1560012, Yinchuan, Not set
Investigational Site Number : 1560028, Zhenjiang, Not set
Investigational Site Number : 2032105, Nový Jičín, Not set
Investigational Site Number : 2032104, Ostrava, Not set
Investigational Site Number : 2032102, Prague, Not set
Investigational Site Number : 2030003, Prague, Not set
Investigational Site Number : 2030006, Prague, Not set
Investigational Site Number : 2030007, Prague, Not set
Investigational Site Number : 2080001, Aarhus, Not set
Investigational Site Number : 2500004, Créteil, Not set
Investigational Site Number : 2500001, Lille, Not set
Investigational Site Number : 2500005, Marseille, Not set
Investigational Site Number : 2500009, Nantes, Not set
Investigational Site Number : 2500003, Paris, Not set
Investigational Site Number : 2500006, Pierre-bénite, Not set
Investigational Site Number : 2500002, Toulouse, Not set
Investigational Site Number : 2760009, Bad Bentheim, Not set
Investigational Site Number : 2762203, Berlin, Not set
Investigational Site Number : 2762201, Münster, Not set
Investigational Site Number : 2760010, Osnabrück, Not set
Investigational Site Number : 3560006, Bangalore, Not set
Investigational Site Number : 3560007, Bikaner, Not set
Investigational Site Number : 3560003, Gurugram, Not set
Investigational Site Number : 3560011, Kochi, Not set
Investigational Site Number : 3560005, Kolkata, Not set
Investigational Site Number : 3560004, Mangaluru, Not set
Investigational Site Number : 3560002, Nashik, Not set
Investigational Site Number : 3560008, Surat, Not set
Investigational Site Number : 3800003, Milan, Milano
Investigational Site Number : 3800002, Naples, Napoli
Investigational Site Number : 3800004, Naples, Napoli
Investigational Site Number : 3800007, Rome, Roma
Investigational Site Number : 3800006, Rome, Roma
Investigational Site Number : 3800005, Brescia, Not set
Investigational Site Number : 3800008, Vicenza, Not set
Investigational Site Number : 3923114, Obihiro, Hokkaido
Investigational Site Number : 3923113, Yokohama, Kanagawa
Investigational Site Number : 3923110, Sakai, Osaka
Investigational Site Number : 3923106, Mibu, Tochigi
Investigational Site Number : 3920001, Tachikawa, Tokyo
Investigational Site Number : 4100002, Ansan-si, Gyeonggi-do
Investigational Site Number : 4100016, Bucheon-si, Gyeonggi-do
Investigational Site Number : 4100003, Yangsan-si, Gyeongsangnam-do
Investigational Site Number : 4100018, Incheon, Incheon-gwangyeoksi
Investigational Site Number : 4100006, Seoul, Seoul-teukbyeolsi
Investigational Site Number : 4100001, Seoul, Seoul-teukbyeolsi
Investigational Site Number : 4840001, Chihuahua, Not set
Investigational Site Number : 4840008, Durango, Not set
Investigational Site Number : 5280002, Breda, Not set
Investigational Site Number : 5280004, Rotterdam, Not set
Investigational Site Number : 5280001, Utrecht, Not set
Investigational Site Number : 6160014, Lodz, Lódzkie
Investigational Site Number : 6162411, Warsaw, Mazowieckie
Investigational Site Number : 6160009, Warsaw, Mazowieckie
Investigational Site Number : 6160007, Warsaw, Mazowieckie
Investigational Site Number : 6160006, Gdansk, Pomorskie
Investigational Site Number : 6160001, Chorzow, Slaskie
Investigational Site Number : 6160003, Katowice, Slaskie
Investigational Site Number : 6160012, Lublin, Not set
Dr. Samuels Sanchez P.S.C.- Site Number : 8400045, Caguas, Not set
GCM Medical Group - San Juan - Calle Jose Marti- Site Number : 8400049, San Juan, Not set
Caribbean Medical Research Center- Site Number : 8400028, San Juan, Not set
Investigational Site Number : 7100004, Boksburg, Not set
Investigational Site Number : 7100011, Cape Town, Not set
Investigational Site Number : 7100010, Cape Town, Not set
Investigational Site Number : 7100002, Cape Town, Not set
Investigational Site Number : 7100009, Cape Town, Not set
Investigational Site Number : 7100012, Durban, Not set
Investigational Site Number : 7100015, Durban, Not set
Investigational Site Number : 7100006, Johannesburg, Not set
Investigational Site Number : 7100007, Johannesburg, Not set
Investigational Site Number : 7100005, Middelburg, Not set
Investigational Site Number : 7100003, Pretoria, Not set
Investigational Site Number : 7100014, Pretoria, Not set
Investigational Site Number : 7240002, Badalona, Barcelona [Barcelona]
Investigational Site Number : 7240022, Sabadell, Castilla Y León
Investigational Site Number : 7242505, Alicante, Not set
Investigational Site Number : 7242501, Córdoba, Not set
Investigational Site Number : 7240021, Madrid, Not set
Investigational Site Number : 7242503, Madrid, Not set
Investigational Site Number : 7240006, Valencia, Not set
Investigational Site Number : 7560002, Buochs, Not set
Investigational Site Number : 1580006, Hsinchu, Not set
Investigational Site Number : 1583201, Kaohsiung City, Not set
Investigational Site Number : 1580002, New Taipei City, Not set
Investigational Site Number : 1583202, Taichung, Not set
Investigational Site Number : 1580007, Taichung, Not set
Investigational Site Number : 1580001, Taipei City, Not set
Investigational Site Number : 1583203, Taoyuan City, Not set
Investigational Site Number : 7920002, Aydin, Not set
Investigational Site Number : 7920003, Izmit, Not set
Investigational Site Number : 7920005, Manisa, Not set
Investigational Site Number : 7920004, Trabzon, Not set
Investigational Site Number : 8260001, London, England
Investigational Site Number : 8262601, London, London, City Of
Investigational Site Number : 8260002, Edinburgh, Not set
Investigational Site Number : 8260004, Sheffield, Not set
Conditions: Dermatitis Atopic
A Clinical Trial to Investigate the Efficacy of Bragg Apple Cider Vinegar on Blood Glucose Control in a Healthy Adult Population
Recruiting
The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. The main question it aims to answer is:
Is there a difference in the incremental area under the curve (iAUC) (from 0 - 120 mins following administration) for venous blood glucose between Bragg ACV liquid and placebo following an acute carbohydrate load.
Participants will \[descr... Read More
The goal of this clinical study is to investigate the efficacy of a Bragg Apple Cider Vinegar (ACV) liquid on postprandial glucose (PPG) excursion compared to a placebo following a standardized acute carbohydrate load. The main question it aims to answer is:
Is there a difference in the incremental area under the curve (iAUC) (from 0 - 120 mins following administration) for venous blood glucose between Bragg ACV liquid and placebo following an acute carbohydrate load.
Participants will \[describe the main tasks participants will be asked to consume 750 mg of Bragg Apple Cider Vinegar (ACV) liquid or water and undergo a blood draw to measure glucose, insulin, and future analysis markers. Read Less
Gender:
ALL
Ages:
Between 20 years and 50 years
Trial Updated:
08/07/2025
Locations: KGK Science Inc., London, Ontario
KGK Science Inc., London, Ontario
Conditions: Healthy, Blood Glucose
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Recruiting
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO). Read Less
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/07/2025
Locations: Ps0021 50162, Fountain Valley, California +47 locations
Ps0021 50162, Fountain Valley, California
Ps0021 50161, Los Angeles, California
Ps0021 50196, Northridge, California
Ps0021 50581, Miami, Florida
Ps0021 50344, Indianapolis, Indiana
Ps0021 50599, Kew Gardens, New York
Ps0021 50084, Charleston, South Carolina
Ps0021 50201, Arlington, Texas
Ps0021 50355, Dallas, Texas
Ps0021 40121, Brussels, Not set
Ps0021 40420, Liege, Not set
Ps0021 50618, Mississauga, Not set
Ps0021 50617, St- John's, Not set
Ps0021 50357, St. John's, Not set
Ps0021 40748, Plzen-bory, Not set
Ps0021 40742, Argenteuil, Not set
Ps0021 40754, Nantes, Not set
Ps0021 40740, Bad Bentheim, Not set
Ps0021 40515, Berlin, Not set
Ps0021 40138, Bonn, Not set
Ps0021 40356, Dresden, Not set
Ps0021 40023, Erlangen, Not set
Ps0021 40645, Frankfurt/main, Not set
Ps0021 40758, Hamburg, Not set
Ps0021 40249, Kiel, Not set
Ps0021 40747, Mainz, Not set
Ps0021 40177, Muenster, Not set
Ps0021 40746, Debrecen, Not set
Ps0021 40744, Kaposvár, Not set
Ps0021 40745, Szeged, Not set
Ps0021 40440, Ancona, Località Torrette, Not set
Ps0021 40749, Catania, Not set
Ps0021 40085, Pisa, Not set
Ps0021 40567, Roma, Not set
Ps0021 20033, Nagoya, Not set
Ps0021 20337, Shimotsuga-gun, Not set
Ps0021 40741, Bialystok, Not set
Ps0021 40625, Lodz, Not set
Ps0021 40091, Nowa Sól, Not set
Ps0021 40737, Rzeszow, Not set
Ps0021 40743, Szczecin, Not set
Ps0021 40334, Wroclaw, Not set
Ps0021 40738, Wroclaw, Not set
Ps0021 40750, Alicante, Not set
Ps0021 40159, Barcelona, Not set
Ps0021 40751, Esplugues de Llobregat, Not set
Ps0021 40752, Granada, Not set
Ps0021 40753, Santiago de Compostela, Not set
Conditions: Moderate to Severe Plaque Psoriasis
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Recruiting
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: GSK Investigational Site, Tucson, Arizona +252 locations
GSK Investigational Site, Tucson, Arizona
GSK Investigational Site, Los Angeles, California
GSK Investigational Site, New Haven, Connecticut
GSK Investigational Site, Washington, District of Columbia
GSK Investigational Site, Deerfield Beach, Florida
GSK Investigational Site, Fort Lauderdale, Florida
GSK Investigational Site, Marietta, Georgia
GSK Investigational Site, Chicago, Illinois
GSK Investigational Site, Chicago, Illinois
GSK Investigational Site, Chicago, Illinois
GSK Investigational Site, Naperville, Illinois
GSK Investigational Site, Naperville, Illinois
GSK Investigational Site, Westwood, Kansas
GSK Investigational Site, Lexington, Kentucky
GSK Investigational Site, Louisville, Kentucky
GSK Investigational Site, Baton Rouge, Louisiana
GSK Investigational Site, Bethesda, Maryland
GSK Investigational Site, Ann Arbor, Michigan
GSK Investigational Site, Detroit, Michigan
GSK Investigational Site, Minneapolis, Minnesota
GSK Investigational Site, Joplin, Missouri
GSK Investigational Site, Saint Louis, Missouri
GSK Investigational Site, Saint Louis, Missouri
GSK Investigational Site, Grand Island, Nebraska
GSK Investigational Site, Omaha, Nebraska
GSK Investigational Site, Omaha, Nebraska
GSK Investigational Site, Lebanon, New Hampshire
GSK Investigational Site, Bronx, New York
GSK Investigational Site, New York, New York
GSK Investigational Site, New York, New York
GSK Investigational Site, New York, New York
GSK Investigational Site, New York, New York
GSK Investigational Site, Durham, North Carolina
GSK Investigational Site, Akron, Ohio
GSK Investigational Site, Cincinnati, Ohio
GSK Investigational Site, Cleveland, Ohio
GSK Investigational Site, Cleveland, Ohio
GSK Investigational Site, Cleveland, Ohio
GSK Investigational Site, Oklahoma City, Oklahoma
GSK Investigational Site, Oklahoma City, Oklahoma
GSK Investigational Site, Pittsburgh, Pennsylvania
GSK Investigational Site, Sioux Falls, South Dakota
GSK Investigational Site, Sioux Falls, South Dakota
GSK Investigational Site, Sioux Falls, South Dakota
GSK Investigational Site, Sioux Falls, South Dakota
GSK Investigational Site, Dallas, Texas
GSK Investigational Site, Dallas, Texas
GSK Investigational Site, Richmond, Virginia
GSK Investigational Site, Appleton, Wisconsin
GSK Investigational Site, Buenos Aires, Not set
GSK Investigational Site, Buenos Aires, Not set
GSK Investigational Site, Buenos Aires, Not set
GSK Investigational Site, Capital Federal, Not set
GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Not set
GSK Investigational Site, Cordoba, Not set
GSK Investigational Site, Mar del Plata, Not set
GSK Investigational Site, Rosario, Not set
GSK Investigational Site, San Miguel de TucumAn, Not set
GSK Investigational Site, Santa Fe, Not set
GSK Investigational Site, Newcastle, New South Wales
GSK Investigational Site, St Leonards, New South Wales
GSK Investigational Site, Woolangabba, Queensland
GSK Investigational Site, Heidelberg, Victoria
GSK Investigational Site, Melbourne, Victoria
GSK Investigational Site, Aalst, Not set
GSK Investigational Site, Bruxelles, Not set
GSK Investigational Site, Bruxelles, Not set
GSK Investigational Site, Edegem, Not set
GSK Investigational Site, Gent, Not set
GSK Investigational Site, Leuven, Not set
GSK Investigational Site, LiEge, Not set
GSK Investigational Site, Roeselare, Not set
GSK Investigational Site, Barretos, Not set
GSK Investigational Site, Lages, Not set
GSK Investigational Site, Natal, Not set
GSK Investigational Site, Porto Alegre, Not set
GSK Investigational Site, Salvador, Not set
GSK Investigational Site, Sao Jose Do Rio Preto, Not set
GSK Investigational Site, Sao Paulo, Not set
GSK Investigational Site, Sao Paulo, Not set
GSK Investigational Site, Teresina, Not set
GSK Investigational Site, VitOria, Not set
GSK Investigational Site, Edmonton, Alberta
GSK Investigational Site, Halifax, Nova Scotia
GSK Investigational Site, Ottawa, Ontario
GSK Investigational Site, Toronto, Ontario
GSK Investigational Site, Montreal, Quebec
GSK Investigational Site, Beijing, Not set
GSK Investigational Site, Beijing, Not set
GSK Investigational Site, Beijing, Not set
GSK Investigational Site, Changchun, Not set
GSK Investigational Site, Chengdu, Not set
GSK Investigational Site, Chongqing, Not set
GSK Investigational Site, Chongqing, Not set
GSK Investigational Site, Guangzhou, Not set
GSK Investigational Site, Guangzhou, Not set
GSK Investigational Site, Hangzhou, Not set
GSK Investigational Site, Hangzhou, Not set
GSK Investigational Site, Hangzhou, Not set
GSK Investigational Site, Hangzhou, Not set
GSK Investigational Site, Harbin, Not set
GSK Investigational Site, Jinan, Not set
GSK Investigational Site, Kunming, Not set
GSK Investigational Site, Meizhou, Not set
GSK Investigational Site, Nanchang, Not set
GSK Investigational Site, Nanchang, Not set
GSK Investigational Site, Shanghai, Not set
GSK Investigational Site, Shanghai, Not set
GSK Investigational Site, Shenzhen, Not set
GSK Investigational Site, Taiyuan, Not set
GSK Investigational Site, Tianjin, Not set
GSK Investigational Site, Wuhan, Not set
GSK Investigational Site, Xiamen, Not set
GSK Investigational Site, Yangzhou, Not set
GSK Investigational Site, Zhengzhou, Not set
GSK Investigational Site, Tallinn, Not set
GSK Investigational Site, Tallinn, Not set
GSK Investigational Site, Tartu, Not set
GSK Investigational Site, Helsinki, Not set
GSK Investigational Site, Tampere, Not set
GSK Investigational Site, Turku, Not set
GSK Investigational Site, Lyon, Not set
GSK Investigational Site, Marseille Cedex 5, Not set
GSK Investigational Site, Nantes cedex 1, Not set
GSK Investigational Site, Paris, Not set
GSK Investigational Site, Pessac cedex, Not set
GSK Investigational Site, Rennes Cedex, Not set
GSK Investigational Site, Rouen Cedex, Not set
GSK Investigational Site, Saint-Priest en Jarez, Not set
GSK Investigational Site, Suresnes, Not set
GSK Investigational Site, Toulouse Cedex 9, Not set
GSK Investigational Site, Villejuif Cedex, Not set
GSK Investigational Site, Berlin, Not set
GSK Investigational Site, Duesseldorf, Not set
GSK Investigational Site, Frankfurt, Not set
GSK Investigational Site, Halle, Not set
GSK Investigational Site, Luebeck, Not set
GSK Investigational Site, Mannheim, Not set
GSK Investigational Site, MUnchen, Not set
GSK Investigational Site, Munchen, Not set
GSK Investigational Site, Athens, Not set
GSK Investigational Site, Thessaloniki, Not set
GSK Investigational Site, Thessaloniki, Not set
GSK Investigational Site, Cagliari, Not set
GSK Investigational Site, Genova, Not set
GSK Investigational Site, Milano, Not set
GSK Investigational Site, Napoli, Not set
GSK Investigational Site, Padova, Not set
GSK Investigational Site, Pisa, Not set
GSK Investigational Site, Reggio Emilia, Not set
GSK Investigational Site, Roma, Not set
GSK Investigational Site, Roma, Not set
GSK Investigational Site, Rozzano MI, Not set
GSK Investigational Site, Aichi, Not set
GSK Investigational Site, Chiba, Not set
GSK Investigational Site, Fukuoka, Not set
GSK Investigational Site, Hokkaido, Not set
GSK Investigational Site, Hyogo, Not set
GSK Investigational Site, Ibaraki, Not set
GSK Investigational Site, Kanagawa, Not set
GSK Investigational Site, Kanagawa, Not set
GSK Investigational Site, Kyoto, Not set
GSK Investigational Site, Okayama, Not set
GSK Investigational Site, Osaka, Not set
GSK Investigational Site, Osaka, Not set
GSK Investigational Site, Osaka, Not set
GSK Investigational Site, Osaka, Not set
GSK Investigational Site, Osaka, Not set
GSK Investigational Site, Shizuoka, Not set
GSK Investigational Site, Tokyo, Not set
GSK Investigational Site, Tokyo, Not set
GSK Investigational Site, Daegu, Not set
GSK Investigational Site, Gyeonggi-do, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, Seoul, Not set
GSK Investigational Site, DF, Not set
GSK Investigational Site, Guadalajara, Not set
GSK Investigational Site, Guadalajara, Not set
GSK Investigational Site, Mexico City, Not set
GSK Investigational Site, Oaxaca, Not set
GSK Investigational Site, San Pedro Garza Garcia, Not set
GSK Investigational Site, Tijuana, Not set
GSK Investigational Site, Breda, Not set
GSK Investigational Site, Maastricht, Not set
GSK Investigational Site, Nijmegen, Not set
GSK Investigational Site, Utrecht, Not set
GSK Investigational Site, Bergen, Not set
GSK Investigational Site, Kristiansand, Not set
GSK Investigational Site, Lrenskog, Not set
GSK Investigational Site, Oslo, Not set
GSK Investigational Site, Stavanger, Not set
GSK Investigational Site, Tromsoe, Not set
GSK Investigational Site, Punta Pacifica Panama City Panama, Not set
GSK Investigational Site, Almada, Not set
GSK Investigational Site, Coimbra, Not set
GSK Investigational Site, Lisboa, Not set
GSK Investigational Site, Badajoz, Not set
GSK Investigational Site, BaracaldoVizcaya, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, Barcelona, Not set
GSK Investigational Site, COrdoba, Not set
GSK Investigational Site, Elche Alicante, Not set
GSK Investigational Site, Granada, Not set
GSK Investigational Site, JaEn, Not set
GSK Investigational Site, L'Hospitalet De Llobrega, Not set
GSK Investigational Site, Las Palmas De Gran Canar, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, MAlaga, Not set
GSK Investigational Site, Oviedo, Not set
GSK Investigational Site, Pamplona, Not set
GSK Investigational Site, San Sebastian, Not set
GSK Investigational Site, Santander, Not set
GSK Investigational Site, Sevilla, Not set
GSK Investigational Site, Valencia, Not set
GSK Investigational Site, Valencia, Not set
GSK Investigational Site, Valencia, Not set
GSK Investigational Site, Zaragoza, Not set
GSK Investigational Site, Eskilstuna, Not set
GSK Investigational Site, Goteborg, Not set
GSK Investigational Site, Linkoping, Not set
GSK Investigational Site, Malmo, Not set
GSK Investigational Site, Stockholm, Not set
GSK Investigational Site, Stockholm, Not set
GSK Investigational Site, Uppsala, Not set
GSK Investigational Site, Kaohsiung, Not set
GSK Investigational Site, Tainan, Not set
GSK Investigational Site, Taipei, Not set
GSK Investigational Site, Taoyuan, Not set
GSK Investigational Site, Ankara, Not set
GSK Investigational Site, Ankara, Not set
GSK Investigational Site, Ankara, Not set
GSK Investigational Site, Istanbul, Not set
GSK Investigational Site, Birmingham, Not set
GSK Investigational Site, Chelmsford, Not set
GSK Investigational Site, Cheltenham, Not set
GSK Investigational Site, Edinburgh, Not set
GSK Investigational Site, Hull, Not set
GSK Investigational Site, Leeds West Yorkshire, Not set
GSK Investigational Site, London, Not set
GSK Investigational Site, London, Not set
GSK Investigational Site, Manchester, Not set
GSK Investigational Site, Sutton, Not set
Conditions: Colonic Neoplasms, Neoplasms, Colon
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Research Site, Mobile, Alabama +450 locations
Research Site, Mobile, Alabama
Research Site, Phoenix, Arizona
Research Site, Phoenix, Arizona
Research Site, Tucson, Arizona
Research Site, Chula Vista, California
Research Site, Fresno, California
Research Site, La Mesa, California
Research Site, Los Angeles, California
Research Site, Newport Beach, California
Research Site, Torrance, California
Research Site, Colorado Springs, Colorado
Research Site, Denver, Colorado
Research Site, Washington, District of Columbia
Research Site, Bradenton, Florida
Research Site, Bradenton, Florida
Research Site, Gainesville, Florida
Research Site, Jacksonville, Florida
Research Site, Lakeland, Florida
Research Site, Miami, Florida
Research Site, Saint Petersburg, Florida
Research Site, South Pasadena, Florida
Research Site, Tampa, Florida
Research Site, Atlanta, Georgia
Research Site, Boise, Idaho
Research Site, Chicago, Illinois
Research Site, Elmhurst, Illinois
Research Site, Evanston, Illinois
Research Site, Fort Wayne, Indiana
Research Site, Iowa City, Iowa
Research Site, Kansas City, Kansas
Research Site, Louisville, Kentucky
Research Site, Baton Rouge, Louisiana
Research Site, New Orleans, Louisiana
Research Site, Shreveport, Louisiana
Research Site, Annapolis, Maryland
Research Site, Silver Spring, Maryland
Research Site, Springfield, Massachusetts
Research Site, Worcester, Massachusetts
Research Site, Detroit, Michigan
Research Site, Royal Oak, Michigan
Research Site, Saint Paul, Minnesota
Research Site, Columbia, Missouri
Research Site, Kansas City, Missouri
Research Site, Saint Louis, Missouri
Research Site, Brooklyn, New York
Research Site, New York, New York
Research Site, New York, New York
Research Site, Potsdam, New York
Research Site, Chapel Hill, North Carolina
Research Site, Greenville, North Carolina
Research Site, Winston-Salem, North Carolina
Research Site, Columbus, Ohio
Research Site, Oklahoma City, Oklahoma
Research Site, Corvallis, Oregon
Research Site, Portland, Oregon
Research Site, Philadelphia, Pennsylvania
Research Site, Providence, Rhode Island
Research Site, Greenville, South Carolina
Research Site, Sioux Falls, South Dakota
Research Site, Dallas, Texas
Research Site, Dallas, Texas
Research Site, El Paso, Texas
Research Site, Houston, Texas
Research Site, Houston, Texas
Research Site, Salt Lake City, Utah
Research Site, Charlottesville, Virginia
Research Site, Green Bay, Wisconsin
Research Site, Milwaukee, Wisconsin
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Caba, Not set
Research Site, Caba, Not set
Research Site, La Plata, Not set
Research Site, Mar del Plata, Not set
Research Site, Munro, Not set
Research Site, Rosario, Not set
Research Site, Adelaide, Not set
Research Site, Bedford Park, Not set
Research Site, New Lambton Heights, Not set
Research Site, Port Macquarie, Not set
Research Site, South Brisbane, Not set
Research Site, Kortrijk, Not set
Research Site, Ottignies, Not set
Research Site, Roeselare, Not set
Research Site, Yvoir, Not set
Research Site, Belo Horizonte, Not set
Research Site, Campinas, Not set
Research Site, Caxias do Sul, Not set
Research Site, Curitiba, Not set
Research Site, Curitiba, Not set
Research Site, Indaiatuba, Not set
Research Site, Jaú, Not set
Research Site, Natal, Not set
Research Site, Niterói, Not set
Research Site, Passo Fundo, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Recife, Not set
Research Site, Ribeirão Preto, Not set
Research Site, Rio de Janeiro, Not set
Research Site, Salvador, Not set
Research Site, Sao Paulo, Not set
Research Site, São Caetano do Sul, Not set
Research Site, São José do Rio Preto, Not set
Research Site, São Paulo, Not set
Research Site, Montana, Not set
Research Site, Pernik, Not set
Research Site, Pleven, Not set
Research Site, Ruse, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Varna, Not set
Research Site, Calgary, Alberta
Research Site, New Westminster, British Columbia
Research Site, Winnipeg, Manitoba
Research Site, Winnipeg, Manitoba
Research Site, Winnipeg, Manitoba
Research Site, Brampton, Ontario
Research Site, Ottawa, Ontario
Research Site, Ottawa, Ontario
Research Site, Toronto, Ontario
Research Site, Levis, Quebec
Research Site, Montreal, Quebec
Research Site, Montréal, Quebec
Research Site, Montréal, Quebec
Research Site, Saskatoon, Saskatchewan
Research Site, Quebec, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Fuyang, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Haikou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hefei, Not set
Research Site, Jining, Not set
Research Site, Nanchang, Not set
Research Site, Nantong, Not set
Research Site, Qingdao, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenzhen, Not set
Research Site, Tianjin, Not set
Research Site, Weifang, Not set
Research Site, Wuhan, Not set
Research Site, Wuhan, Not set
Research Site, Yantai, Not set
Research Site, Yinchuan, Not set
Research Site, Yueyang, Not set
Research Site, Zhengzhou, Not set
Research Site, Bogota DC, Not set
Research Site, Floridablanca, Not set
Research Site, Medellin, Not set
Research Site, Soledad, Not set
Research Site, Villavicencio, Not set
Research Site, Benesov, Not set
Research Site, Brno, Not set
Research Site, Hradec Kralove, Not set
Research Site, Kolin, Not set
Research Site, Kyjov, Not set
Research Site, Mlada Boleslav, Not set
Research Site, Praha 10, Not set
Research Site, Praha 5, Not set
Research Site, Praha, Not set
Research Site, Aalborg, Not set
Research Site, Aarhus N, Not set
Research Site, Copenhagen Ø, Not set
Research Site, Herning, Not set
Research Site, Hillerød, Not set
Research Site, Hvidovre, Not set
Research Site, Kolding, Not set
Research Site, København, Not set
Research Site, Odense C, Not set
Research Site, Vejle, Not set
Research Site, Alexandria, Not set
Research Site, Cairo, Not set
Research Site, Cairo, Not set
Research Site, New Cairo, Not set
Research Site, Amiens Cedex 1, Not set
Research Site, Angers, Not set
Research Site, Brest Cedex, Not set
Research Site, Créteil, Not set
Research Site, Dijon, Not set
Research Site, La Tronche, Not set
Research Site, Le Coudray Cedex, Not set
Research Site, Montpellier Cedex 5, Not set
Research Site, Nantes Cedex 1, Not set
Research Site, Orléans Cedex 2, Not set
Research Site, Strasbourg Cedex, Not set
Research Site, Strasbourg, Not set
Research Site, Tours, Not set
Research Site, Augsburg, Not set
Research Site, Berlin, Not set
Research Site, Berlin, Not set
Research Site, Hamburg, Not set
Research Site, Hannover, Not set
Research Site, Kiel, Not set
Research Site, Köln, Not set
Research Site, Leverkusen, Not set
Research Site, Marburg, Not set
Research Site, Regensburg, Not set
Research Site, Rosenheim, Not set
Research Site, Rostock, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Exohi Thessaloniki, Not set
Research Site, Heraklion, Not set
Research Site, Ioannina, Not set
Research Site, Thessaloniki, Not set
Research Site, Hong Kong, Not set
Research Site, Shatin, Not set
Research Site, Balassagyarmat, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Debrecen, Not set
Research Site, Győr, Not set
Research Site, Kistarcsa, Not set
Research Site, Nyíregyháza, Not set
Research Site, Pécs, Not set
Research Site, Ahmedabad, Not set
Research Site, Ahmedabad, Not set
Research Site, Belagavi, Not set
Research Site, Chennai, Not set
Research Site, Gurgaon, Not set
Research Site, Gurugram, Not set
Research Site, Hyderabad, Not set
Research Site, Hyderabad, Not set
Research Site, Kanpur, Not set
Research Site, Mumbai, Not set
Research Site, New Delhi, Not set
Research Site, New Delhi, Not set
Research Site, New Delhi, Not set
Research Site, Pune, Not set
Research Site, Thane, Not set
Research Site, Vijayawada, Not set
Research Site, Afula, Not set
Research Site, Ashkelon, Not set
Research Site, Beer Sheva, Not set
Research Site, Haifa, Not set
Research Site, Holon, Not set
Research Site, Jerusalem, Not set
Research Site, Petah-Tikva, Not set
Research Site, Ramat Gan, Not set
Research Site, Rehovot, Not set
Research Site, Arezzo, Not set
Research Site, Brescia, Not set
Research Site, Napoli, Not set
Research Site, Roma, Not set
Research Site, Roma, Not set
Research Site, Rozzano, Not set
Research Site, Torino, Not set
Research Site, Chiba-shi, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Gifu-shi, Not set
Research Site, Ginowan-shi, Not set
Research Site, Hanyu-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Hitachi-shi, Not set
Research Site, Isehara-shi, Not set
Research Site, Izumisano-shi, Not set
Research Site, Izumo-shi, Not set
Research Site, Kamakura-shi, Not set
Research Site, Kamogawa-shi, Not set
Research Site, Kanazawa-shi, Not set
Research Site, Kanazawa-shi, Not set
Research Site, Kasuga-shi, Not set
Research Site, Kawasaki-shi, Not set
Research Site, Koshigaya-shi, Not set
Research Site, Kumagaya-shi, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Kusatsu-shi, Not set
Research Site, Kyoto-shi, Not set
Research Site, Kyoto-shi, Not set
Research Site, Maebashi-shi, Not set
Research Site, Meguro-ku, Not set
Research Site, Mitaka-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nerima-ku, Not set
Research Site, Okayama-shi, Not set
Research Site, Okazaki-shi, Not set
Research Site, Omuta-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Shinagawa-ku, Not set
Research Site, Shinjuku-ku, Not set
Research Site, Suita-shi, Not set
Research Site, Tachikawa-shi, Not set
Research Site, Takamatsu-shi, Not set
Research Site, Urasoe-shi, Not set
Research Site, Ureshino-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Daegu, Not set
Research Site, Jeonju, Not set
Research Site, Seoul, Not set
Research Site, Kota Kinabalu, Not set
Research Site, Kuala Lumpur, Not set
Research Site, Kuala Lumpur, Not set
Research Site, Kuala Terengganu, Not set
Research Site, Kuantan, Not set
Research Site, Kubang Kerian, Not set
Research Site, Melaka, Not set
Research Site, Petaling Jaya, Not set
Research Site, Pulau Pinang, Not set
Research Site, Sarawak Miri, Not set
Research Site, Selangor Darul Ehsan, Not set
Research Site, Shah Alam, Not set
Research Site, Aguascalientes, Not set
Research Site, Ciudad de México, Not set
Research Site, Guadalajara, Not set
Research Site, Guadalajara, Not set
Research Site, Mexico City, Not set
Research Site, Monterrey, Not set
Research Site, San Luis Potosi, Not set
Research Site, Tlalpan, Not set
Research Site, Tlalpan, Not set
Research Site, Xalapa, Not set
Research Site, Cusco, Not set
Research Site, el Agustino, Not set
Research Site, LIma, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Piura, Not set
Research Site, Cebu, Not set
Research Site, Iloilo City, Not set
Research Site, Manila, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, Chrzanów, Not set
Research Site, Rzeszów, Not set
Research Site, Warszawa, Not set
Research Site, Warszawa, Not set
Research Site, Warszawa, Not set
Research Site, Wroclaw, Not set
Research Site, Łańcut, Not set
Research Site, Łódź, Not set
Research Site, Łęczna, Not set
Research Site, Bayamon, Not set
Research Site, Bucharest, Not set
Research Site, Bucharest, Not set
Research Site, Cluj-Napoca, Not set
Research Site, Constanta, Not set
Research Site, Iasi, Not set
Research Site, Sibiu, Not set
Research Site, Timisoara, Not set
Research Site, Jeddah, Not set
Research Site, Riyadh, Not set
Research Site, Riyadh, Not set
Research Site, Riyadh, Not set
Research Site, Bratislava, Not set
Research Site, Johannesburg, Soweto, Not set
Research Site, Observatory, Not set
Research Site, Parktown, Not set
Research Site, Westdene, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Madrid, Not set
Research Site, Majadahonda, Not set
Research Site, Málaga, Not set
Research Site, Ourense, Not set
Research Site, Palma de Mallorca, Not set
Research Site, Pamplona, Not set
Research Site, Santander, Not set
Research Site, Valencia, Not set
Research Site, Helsingborg, Not set
Research Site, Huddinge, Not set
Research Site, Lund, Not set
Research Site, Malmö, Not set
Research Site, Solna, Not set
Research Site, Stockholm, Not set
Research Site, Stockholm, Not set
Research Site, Umeå, Not set
Research Site, Västerås, Not set
Research Site, Kaohsiung, Not set
Research Site, Kaohsiung, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Taipei, Not set
Research Site, Taipei, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan City, Not set
Research Site, Taoyuan, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Banphaeo, Not set
Research Site, Chiang Mai, Not set
Research Site, Khlong Luang, Not set
Research Site, Khon-Kaen, Not set
Research Site, Phutthamonthon, Not set
Research Site, Ubonratchathani, Not set
Research Site, Ankara, Not set
Research Site, Diyarbakir, Not set
Research Site, Istambul, Not set
Research Site, Istanbul, Not set
Research Site, Istanbul, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Izmir, Not set
Research Site, İzmit, Not set
Research Site, Malatya, Not set
Research Site, Ortahisar, Not set
Research Site, Bristol, Not set
Research Site, Dundee, Not set
Research Site, Glasgow, Not set
Research Site, Glasgow, Not set
Research Site, Hampshire, Not set
Research Site, Huddersfield, Not set
Research Site, Leeds, Not set
Research Site, Leicester, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Oxford, Not set
Research Site, Prescot, Not set
Research Site, Tyne And Wear, Not set
Research Site, Wythenshawe, Not set
Research Site, Hai Phong, Not set
Research Site, Hai Phong, Not set
Research Site, Hanoi, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh, Not set
Research Site, Ho Chi Minh, Not set
Research Site, Ho Chi Minh, Not set
Research Site, Hochiminh city, Not set
Research Site, Hue, Not set
Conditions: Viral Lung Infection and Acute Respiratory Failure
FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)
Recruiting
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment.
Study details include:
Screening period: at least 3 weeks and up to 5 weeks
Double-blind treatment period (104 weeks):
* Main treatment period: 52 weeks
* Blinded extension: 52 weeks Optional Open Label Extension: 104 weeks Safety follow-up:... Read More
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment.
Study details include:
Screening period: at least 3 weeks and up to 5 weeks
Double-blind treatment period (104 weeks):
* Main treatment period: 52 weeks
* Blinded extension: 52 weeks Optional Open Label Extension: 104 weeks Safety follow-up: up to 26 weeks The treatment duration will be up to 104 weeks, the total study duration will be up to 135 weeks. Read Less
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
08/07/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400012, San Francisco, California +73 locations
University of California San Francisco - Mission Bay- Site Number : 8400012, San Francisco, California
University of Colorado- Site Number : 8400003, Denver, Colorado
University of Florida College of Medicine- Site Number : 8400010, Gainesville, Florida
University of Miami Hospital- Site Number : 8400013, Miami, Florida
AdventHealth Orlando- Site Number : 8400002, Orlando, Florida
Rocky Mountain Diabetes and Osteoporosis Center- Site Number : 8400009, Idaho Falls, Idaho
NorthShore University HealthSystem - Skokie- Site Number : 8400007, Skokie, Illinois
Joslin Diabetes Center - Boston- Site Number : 8400015, Boston, Massachusetts
University at Buffalo - Downtown Campus- Site Number : 8400004, Buffalo, New York
University of North Carolina at Chapel Hill- Site Number : 8400001, Chapel Hill, North Carolina
Cincinnati Children's Hospital Medical Center- Site Number : 8400019, Cincinnati, Ohio
The Children's Hospital of Philadelphia Site Number : 8400005, Philadelphia, Pennsylvania
University of Texas - Southwestern Medical Center- Site Number : 8400011, Dallas, Texas
Benaroya Research Institute at Virginia Mason- Site Number : 8400016, Seattle, Washington
Investigational Site Number : 0560002, Brussels, Not set
Investigational Site Number : 0560001, Leuven, Not set
Investigational Site Number : 1240001, Vancouver, British Columbia
Investigational Site Number : 1240007, London, Ontario
Investigational Site Number : 1240005, Montreal, Quebec
Investigational Site Number : 1240004, Montreal, Quebec
Investigational Site Number : 1240003, Montreal, Quebec
Investigational Site Number : 2030003, Ostrava, Not set
Investigational Site Number : 2030002, Prague, Not set
Investigational Site Number : 2030001, Prague, Not set
Investigational Site Number : 2030004, Ústí Nad Labem, Not set
Investigational Site Number : 2080005, Herlev, Not set
Investigational Site Number : 2460003, Tampere, Not set
Investigational Site Number : 2500004, Corbeil-essonnes, Not set
Investigational Site Number : 2500005, Mont-de-marsan, Not set
Investigational Site Number : 2500006, Paris, Not set
Investigational Site Number : 2500007, Pontoise, Not set
Investigational Site Number : 2500003, Saint-herblain, Not set
Investigational Site Number : 2760003, Dresden, Not set
Investigational Site Number : 2760001, Hannover, Not set
Investigational Site Number : 2760002, Oldenburg in Holstein, Not set
Investigational Site Number : 2760004, Ulm, Not set
Investigational Site Number : 3480001, Balatonfüred, Not set
Investigational Site Number : 3480004, Budapest, Not set
Investigational Site Number : 3480002, Nyíregyháza, Not set
Investigational Site Number : 3480006, Székesfehérvár, Not set
Investigational Site Number : 3800008, Torette, Ancona
Azienda Ospedaliera Universitaria Meyer IRCCS-Site Number : 3800003, Florence, Firenze
IRCCS Ospedale San Raffaele-Site Number : 3800006, Milan, Milano
Azienda Ospedaliera Universitaria 'Federico II'-Site Number : 3800009, Naples, Napoli
Investigational Site Number : 3800007, Rome, Roma
Azienda Ospedaliero-Universitaria Maggiore Della Carità-Site Number : 3800001, Novara, Not set
Investigational Site Number : 3800005, Novara, Not set
Azienda Socio Sanitaria Territoriale Dei Sette Laghi - Ospedale Filippo del Ponte-Site Number : 3800002, Varese, Not set
Azienda Ospedaliera Universitaria Integrata Verona - Centro regionale di Diabetologia Pediatrica-Site Number : 3800004, Verona, Not set
Investigational Site Number : 6160004, Warsaw, Mazowieckie
Investigational Site Number : 6160001, Warsaw, Mazowieckie
Investigational Site Number : 6160007, Warsaw, Mazowieckie
Investigational Site Number : 6160002, Katowice, Slaskie
Investigational Site Number : 6160008, Bialystok, Not set
Investigational Site Number : 6160005, Lodz, Not set
Investigational Site Number : 6160009, Szczecin, Not set
Investigational Site Number : 6160006, Warszawa, Not set
Investigational Site Number : 7240005, Oviedo, Asturias
Investigational Site Number : 7240001, Barcelona, Barcelona [Barcelona]
Investigational Site Number : 7240002, Esplugues de Llobregat, Barcelona [Barcelona]
Investigational Site Number : 7240003, Seville, Sevilla
Investigational Site Number : 7240004, Málaga, Not set
Investigational Site Number : 7240006, Valencia, Not set
Investigational Site Number : 7240007, Vitoria-gasteiz, Álava
Investigational Site Number : 7520002, Solna, Not set
Investigational Site Number : 7520001, Stockholm, Not set
Investigational Site Number : 7520003, Stockholm, Not set
Investigational Site Number : 8260001, Cambridge, Cambridgeshire
Investigational Site Number : 8260003, Birmingham, England
Investigational Site Number : 8260007, Birmingham, England
Investigational Site Number : 8260010, Glasgow, Glasgow City
Investigational Site Number : 8260004, Leicester, Leicestershire
Investigational Site Number : 8260006, Harrow, London, City Of
Investigational Site Number : 8260009, Dundee, Scotland
Conditions: Type 1 Diabetes Mellitus
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Recruiting
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: Research Site, Eden Prairie, Minnesota +25 locations
Research Site, Eden Prairie, Minnesota
Research Site, Calgary, Alberta
Research Site, Beijing, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Guangzhou, Not set
Research Site, Wuhan, Not set
Research Site, Horsens, Not set
Research Site, Berlin, Not set
Research Site, Tokyo, Not set
Research Site, Lisbona, Not set
Research Site, Porto, Not set
Research Site, A Coruna, Not set
Research Site, Barcelona, Not set
Research Site, Bilbao, Not set
Research Site, El Palmar, Not set
Research Site, Huelva, Not set
Research Site, Las Palmas de Gran Canaria, Not set
Research Site, Madrid, Not set
Research Site, Majadahonda, Not set
Research Site, Palma de Mallorca, Not set
Research Site, Salamanca, Not set
Research Site, Valencia, Not set
Research Site, Sodertalje, Not set
Research Site, Umea, Not set
Research Site, London, Not set
Conditions: ATTR Amyloidosis
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Recruiting
The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype.
Screening period: 2 to up to 4 weeks
Treatment period:
52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of... Read More
The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype.
Screening period: 2 to up to 4 weeks
Treatment period:
52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of open-label dupilumab therapy for study participants who qualify. Follow-up period: 12 weeks The maximum duration of study per participant is up to 68 weeks. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: Om Research- Site Number : 8400029, Apple Valley, California +76 locations
Om Research- Site Number : 8400029, Apple Valley, California
TLC Clinical Research- Site Number : 8400020, Beverly Hills, California
Ventura County Gastroenterology Medical Group- Site Number : 8400028, Camarillo, California
Palmtree Clinical Research- Site Number : 8400048, Palm Springs, California
Clinical Trials Management Services - Thousand Oaks- Site Number : 8400034, Thousand Oaks, California
Homestead Associates in Research- Site Number : 8400004, Homestead, Florida
Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400009, Miami Lakes, Florida
GI PROS Research- Site Number : 8400046, Naples, Florida
Advanced Research Institute - New Port Richey- Site Number : 8400026, New Port Richey, Florida
Digestive Disease Consultants - Orange Park- Site Number : 8400042, Orange Park, Florida
Tellabio International Research Services- Site Number : 8400041, Pembroke Pines, Florida
GCP Clinical Research- Site Number : 8400014, Tampa, Florida
Gastroenterology Consultants - Roswell- Site Number : 8400022, Roswell, Georgia
Sanmora Bespoke Clinical Research Solutions- Site Number : 8400043, East Orange, New Jersey
Smart Medical Research Inc- Site Number : 8400037, Jackson Heights, New York
DiGiovanna Family Care- Site Number : 8400006, Massapequa, New York
Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400008, Charlotte, North Carolina
Care Access - Lumberton- Site Number : 8400018, Lumberton, North Carolina
UPMC Presbyterian- Site Number : 8400038, Pittsburgh, Pennsylvania
Advanced Gastroenterology Associates, PA- Site Number : 8400047, Decatur, Texas
Katy Integrative Gastroenterology- Site Number : 8400027, Katy, Texas
Medrasa Clinical Research - Medrasa Sherman- Site Number : 8400039, Sherman, Texas
Texas Digestive Disease Consultants - Southlake- Site Number : 8400013, Southlake, Texas
Digestive Health Specialists of Tyler- Site Number : 8400031, Tyler, Texas
Victoria Gastroenterology- Site Number : 8400019, Victoria, Texas
Washington Gastroenterology - Bellevue- Site Number : 8400025, Bellevue, Washington
Washington Gastroenterology - Tacoma- Site Number : 8400030, Tacoma, Washington
Investigational Site Number : 0320006, Mar Del Plata, Buenos Aires
Investigational Site Number : 0320001, San Miguel de Tucumán, Tucumán
Investigational Site Number : 0320004, San Miguel de Tucumán, Tucumán
Investigational Site Number : 0320007, Buenos Aires, Not set
Investigational Site Number : 0320008, Buenos Aires, Not set
Investigational Site Number : 0320002, Buenos Aires, Not set
Investigational Site Number : 1240007, Edmonton, Alberta
Investigational Site Number : 1240010, Scarborough, Ontario
Investigational Site Number : 1240006, Montreal, Quebec
Investigational Site Number : 1240003, Montreal, Quebec
Investigational Site Number : 1520001, Concepción, Biobío
Investigational Site Number : 1520005, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520003, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520006, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 1520002, Santiago, Reg Metropolitana De Santiago
Investigational Site Number : 3920006, Nagoya, Aichi
Investigational Site Number : 3920005, Kashiwa, Chiba
Investigational Site Number : 3920008, Kitakyushu, Fukuoka
Investigational Site Number : 3920002, Sapporo, Hokkaido
Investigational Site Number : 3920001, Sapporo, Hokkaido
Investigational Site Number : 3920011, Kamakura, Kanagawa
Investigational Site Number : 3920010, Shimizu, Shizuoka
Investigational Site Number : 3920004, Bunkyo, Tokyo
Investigational Site Number : 3920007, Kyoto, Not set
Investigational Site Number : 3920009, Saitama, Not set
Investigational Site Number : 4100003, Haeundae-gu, Busan-gwangyeoksi
Investigational Site Number : 4100005, Daegu, Daegu-gwangyeoksi
Investigational Site Number : 4100006, Daejeon, Daejeon-gwangyeoksi
Investigational Site Number : 4100002, Wonju-si, Gangwon-do
Investigational Site Number : 4100004, Daegu, Gyeongsangbuk-do
Investigational Site Number : 4840004, Mexico City, Ciudad De Mexico
Investigational Site Number : 4840005, Saltillo, Coahuila De Zaragoza
Investigational Site Number : 4840002, Torreón, Coahuila De Zaragoza
Investigational Site Number : 4840007, Guadalajara, Jalisco
Investigational Site Number : 4840003, Chihuahua, Not set
University of Puerto Rico - Medical Sciences Campus- Site Number : 6300002, San Juan, Not set
Investigational Site Number : 7100005, Cape Town, Not set
Investigational Site Number : 7100009, Cape Town, Not set
Investigational Site Number : 7100002, Cape Town, Not set
Investigational Site Number : 7100007, Cape Town, Not set
Investigational Site Number : 7100003, Gqeberha, Not set
Investigational Site Number : 7100008, Johannesburg, Not set
Investigational Site Number : 7100006, Johannesburg, Not set
Investigational Site Number : 7100001, Johannesburg, Not set
Investigational Site Number : 7100004, Pretoria, Not set
Investigational Site Number : 1580002, Taichung, Not set
Investigational Site Number : 7920003, Gaziantep, Not set
Investigational Site Number : 7920005, Istanbul, Not set
Investigational Site Number : 7920001, Mersin, Not set
Investigational Site Number : 7920006, Zonguldak, Not set
Conditions: Colitis Ulcerative
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Recruiting
Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). In participants with metastatic castration-resistant prostate cancer (mCRPC), the cancer of the prostate has spread to other parts of the body (metastatic) and does not respond to the lowering of testosterone levels in the body (castration resistant). The cancer is 'advanced' and is unlikely to be cured or controlled with currently available treatments. Despite new... Read More
Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). In participants with metastatic castration-resistant prostate cancer (mCRPC), the cancer of the prostate has spread to other parts of the body (metastatic) and does not respond to the lowering of testosterone levels in the body (castration resistant). The cancer is 'advanced' and is unlikely to be cured or controlled with currently available treatments. Despite new treatment options for participant(s) with prostate cancer in recent years, the cancer often returns and worsens.
The study treatment actinium-225-macropa-pelgifatamab (also called 225Ac-pelgi or BAY3546828) is a new type of treatment under development for participants with mCRPC who have already received available treatments or have few treatment options available. It works by binding to a protein on the surface of the cancer cells called prostate specific membrane antigen (PSMA). As it gives off a type of radioactivity that travels a very short distance, it kills the nearby (cancer) cells that express PSMA.
The main purpose of this first-in-human study in participants with mCRPC is to learn:
* How safe different doses of 225Ac-pelgi are.
* To what degree medical problems caused by 225Ac-pelgi can be tolerated by the participants?
* Which dose of 225Ac-pelgi is optimal for treatment (safe and working well)?
* How good is 225Ac-pelgi's anticancer activity?
To answer this, the researchers will look at:
* The number and severity of medical problems that the participants have after treatment with 225Ac-pelgi (per dose level).
* The ratio of medical problems and anticancer activity per dose.
* Anticancer activity of the optimal 225Ac-pelgi dose as proportion of participants who have at least halved prostate-specific antigen (PSA) levels after 12 weeks of treatment or later and/or shrunken or no longer detectable tumors.
* The lowest PSA level reached after treatment start.
Doctors keep track of all medical problems (also called adverse events) that participants have during the study, even if they do not think that they might be related to the study treatment.
Anticancer activity is measured using cancer imaging techniques and change in blood level of a protein called PSA. PSA is made by normal and by cancerous cells in the body. The PSA level is taken as a marker for prostate cancer development and is usually elevated in participants with mCRPC.
In addition, researchers want to find out how 225Ac-pelgi moves into, through and out of the body.
The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose and schedule that can be given in the second part of the study. For this, each participant will receive one of the predefined increasing doses of 225Ac-pelgi as an infusion into the vein. All participants in part 2, called dose expansion, will receive the most appropriate dose and schedule identified from the first part of the study. More than one dose level or schedule from part 1 may be tested. Both the participants and the study team know what treatment the participants will take.
Participants in this study will take the study treatment 225Ac-pelgi once in a period of 6 weeks called a cycle. Each participant will have 4 of these treatment cycles, if the participant benefits from the treatment.
Each participant will be in the study for up to nearly six years, including a first test (screening) phase of a maximum of 30 days, up to 12 months of treatment depending on the participant's benefit, and a follow-up phase of 60 months after the end of treatment. The following visits to the study site are planned: 2 during the screening phase, 8 in the first treatment cycle, 7 in subsequent cycles, and a visit 6 to 12 weeks after the last dose. In the following 12 months, visits are planned every 6 weeks and during the next 48 months phone calls or clinic visits are planned approximately every 12 weeks.
In addition, a sub study during the dose escalation part will gather information on the distribution of the study treatment in the body, the proportion that binds to the cancer cells, and the resulting radiation at the tumor site.
During the study, the study team will:
* Do physical examinations
* Check vital signs such as blood pressure, heart rate, and body temperature
* Take blood, and urine samples
* Examine heart health using echocardiogram and electrocardiogram (ECG)
* Take tumor samples
* Track 225Ac-pelgi in the body using gamma imaging (generally available at all study sites)
* Check the tumor status using PET (positron emission tomography), CT (computed tomography) or MRI (magnetic resonance imaging) and bone scan
* Ask questions about the impact of the disease on the participants' wellbeing and activities of daily life (Eastern Cooperative Oncology Group Performance status (ECOG PS)). Read Less
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/07/2025
Locations: City of Hope - Duarte Cancer Center, Duarte, California +29 locations
City of Hope - Duarte Cancer Center, Duarte, California
University of Minnesota Medical Center, Minneapolis, Minnesota
XCancer Omaha, Omaha, Nebraska
University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas
Utah Cancer Specialists (UCS) (Intermountain Hematology - Oncology Associates) - UCS Cancer Center, Salt Lake City, Utah
Cross Cancer Institute, Clinical Trials Unit, Edmonton, Alberta
BC Cancer - Vancouver Site, Vancouver, British Columbia
Juravinski Cancer Centre - Clinical Trials Department, Hamilton, Ontario
Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology, Toronto, Ontario
Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopi, Montreal, Quebec
McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM), Montreal, Quebec
Centre Hospitalier Universitaire de Sherbrooke (CHUS) - Hopital Fleurimont, Sherbrooke, Not set
Kuopio University Hospital, Kuopio, Pohjois-Savo
HUS, Meilahden sairaala, Helsinki, Uusimaa
Docrates Mehiläinen Syöpäsairaala, Helsinki, Uusimaa
Tampere University Hospital, Tampere, Not set
CRST Clinical Research Services Turku, Turku, Not set
Istituto Europeo di Oncologia s.r.l - Medicina Nucleare, Milano, Not set
IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Medicina Nucleare e Terapia Metabolica, Napoli, Not set
Universitair Medisch Centrum Groningen, Groningen, Not set
Erasmus Medisch Centrum, Rotterdam, Not set
Sahlgrenska Universitetssjukhuset - Klinisk prövningsenhet Fas I/FIH, Göteborg, Not set
Skånes Universitetssjukhus Lund - Onkologens kliniska forskningsenhet, Lund, Not set
Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC, Stockholm, Not set
Akademiska Sjukhuset - Fas-I-enheten, Uppsala, Not set
Kantonsspital Baden, Baden, Aargau
Cambridge University Hospitals NHS Foundation Trust | Addenbrookes Hospital - Clinical Research Centre, Cambridge, Cambridgeshire
Royal Marsden NHS Trust (Surrey), Sutton, Surrey
University College London Hospitals NHS Foundation Trust, London, Not set
The Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital - Cancer Trials Research Centre, Newcastle upon Tyne, Not set
Conditions: Metastatic Castration-resistant Prostate Cancer
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Medical Dermatology Specialists Phoenix, Phoenix, Arizona +135 locations
Medical Dermatology Specialists Phoenix, Phoenix, Arizona
Investigate Md, Scottsdale, Arizona
Premier Dermatology Clinical Trials Institute At Northwest Arkansas, Fayetteville, Arkansas
First Oc Dermatology Research Inc, Fountain Valley, California
Dermatology Research Associates, Los Angeles, California
Integrative Skin Science and Research, Sacramento, California
Clinical Science Institute Clinical Research Specialists Inc, Santa Monica, California
Center For Clinical and Cosmetic Research, Aventura, Florida
Clearlyderm Dermatology, Boca Raton, Florida
Driven Research Llc, Coral Gables, Florida
Direct Helpers Research Center, Hialeah, Florida
Boynton Beach Facility, Hollywood, Florida
Skin Care Research, Llc, Hollywood, Florida
University of Miami Miller School of Medicine, Miami, Florida
Ziaderm Research, Llc, Miami, Florida
Dh Tamarac Research Center Etna Medical Center Emc, Tamarac, Florida
Nodal Medical Center, Llc, Tampa, Florida
Trueblue Clinical Research Moore Clinical Research, Inc McR Tampa Clinic Location, Tampa, Florida
Chicago Cosmetic Surgery and Dermatology, Chicago, Illinois
Dermatology Specialists Research Indiana, Clarksville, Indiana
Southern Indiana Clinical Trials, New Albany, Indiana
Dermatology Specialists Research, Louisville, Kentucky
University of Maryland School of Medicine, Baltimore, Maryland
Dermatology Associates Pc, Rockville, Maryland
Metro Boston Clinical Partners, Brighton, Massachusetts
Fivenson Dermatology, Ann Arbor, Michigan
Henry Ford Health System, Detroit, Michigan
Hamzavi Dermatology, Fort Gratiot, Michigan
Michigan Dermatology Institute, Waterford, Michigan
Medisearch Clinical Trials, Saint Joseph, Missouri
Washington University School of Medicine, Saint Louis, Missouri
Allcutis Research, Llc, Portsmouth, New Hampshire
Schweiger Dermatology, Hackensack, New Jersey
Montefiore Medical Center, Bronx, New York
Suny Downstate Medical Center, Brooklyn, New York
Equity Medical, Llc, New York, New York
OPTISKIN, New York, New York
Oakview Dermatology, Athens, Ohio
University of Cincinnati Cancer Institute, Cincinnati, Ohio
Centricity Research Aventiv Research Dublin, Dublin, Ohio
Central Sooner Research, Oklahoma City, Oklahoma
Paddington Testing Co Inc, Philadelphia, Pennsylvania
Yardley Dermatology Associates, Yardley, Pennsylvania
International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Modern Research Associates Pllc, Dallas, Texas
University of Utah Midvalley Dermatology, Murray, Utah
Aesthetic General Dermatology of Seattle, Burien, Washington
West Virginia Research Institute, Morgantown, West Virginia
Premier Specialists Pty Ltd, Kogarah, New South Wales
Novatrials, Newcastle, New South Wales
Skin & Cancer Foundation Australia, Sydney, New South Wales
Westmead Hospital, Westmead, New South Wales
Veracity Clinical Research Pty Ltd, Wolloongabba, Queensland
The Alfred Hospital, Melbourne, Victoria
Fremantle Dermatology, Fremantle, Not set
Az Sint-Jan Brugge Av, Brugge, Not set
Universitair Ziekenhuis Gent (Uz Gent), Gent, Not set
Centre Hospitalier Universitaire (Chu) de Liege - Domaine Universitaire Du Sart Tilman, Liege, Not set
Grand Hopital de Charleroi ¿ Site Imtr, Loverval, Not set
Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc, Woluwe-saint-lambert, Not set
Skin Physicians, Edmonton, Alberta
Alpha Research-Lucere Dermatology and Laser Clinic, Edmonton, Alberta
Simcoderm Medical and Surgical Dermatology Centre, Barrie, Ontario
Dermeffects, London, Ontario
North York Research Inc., Toronto, Ontario
Toronto Research Centre, Toronto, Ontario
Centre de Recherche Saint-Louis, Quebec City, Quebec
Skinsense Medical Research, Saskatoon, Saskatchewan
Centro Medico Skinmed Limitada, LAS Condes Santiago, Not set
Centro Internacional de Estudios Clinicos, Santiago, Not set
Clinical Research Chile Spa., Valdivia, Not set
Clintrial S.R.O., Prague, Not set
Sanatorium Profesora Arenbergera, Prague, Not set
Sanixtra Prague, Praha 13-stodulky, Not set
University Hospital Rwth Aachen, Aachen, Not set
Elbe Kliniken Buxtehude, Buxtehude, Not set
Drk Krankenhaus Chemnitz-Rabenstein, Chemnitz, Not set
Klinikum Darmstadt, Darmstadt, Not set
Rosenpark Research Gmbh, Darmstadt, Not set
University Hospital Carl Gustav Carus, Dresden, Not set
Klinikum Der Johann Wolfgang Goethe-Universitaet, Frankfurt Am Main, Not set
Universitaetsmedizin Goettingen, Gottingen, Not set
Magdeburger Company For Medical Studies and Services Gmbh, Magdeburg, Not set
Dermatologische Gemeinschaftspraxis Dres. Quist, Mainz, Not set
Technischen Universitaet Muenchen, Muenchen, Not set
University Hospital Muenster, Muenster, Not set
Klinikum Oldenburg Aor, Oldenburg, Not set
Hautarztpraxis Dr. Hoffmann, Witten, Not set
Tokyo Medical and Dental University Hospital, Faculty of Medicine, Bunkyo-ku, Not set
Tokyo Medical University Ibaraki Medical Center - Kasumigaura Campus (Tokyo Medical University Kasum, Inashiki-gun, Not set
Noguchi Dermatology Clinic, Kamimashiki-gun, Not set
Nippon Medical School Musashikosugi Hospital, Kawasaki-shi, Not set
University of Occupational and Environmental Health, Japan, Kitakyushu, Not set
Shimizu Dermatology Clinic, Kobe, Not set
Dokkyo Medical University Saitama Medical Center, Minamikoshigaya, Not set
Niigata University Medical & Dental Hospital, Niigata, Not set
Medical Corporation Jun Dermatology Clinic, Osaka, Not set
Tanpopo Dermatology Clinic, Ota-ku, Not set
Kume Derma Clinic, Sakai, Not set
Sapporo Skin Clinic, Sapporo, Not set
Tohoku University Hospital, Sendai, Not set
Tokyo Medical University Hospital, Shinjuku-ku, Not set
National Defence Medical College Hospital, Tokorozawa-shi, Not set
Akk Medical Sp. Z O.O. - Centrum Medyczne Tu Sie Leczy, Gdansk, Not set
Care Clinic Sp. Z O.O., Katowice, Not set
Santa Familia Ptg Lodz, Lodz, Not set
Dermoklinika Centrum Medyczne S.C., M. Kierstan, J. Narbutt, A. Lesiak, Lodz, Not set
Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Dr. Hab. N. Med. Dorota Krasowska, Lublin, Not set
Dermedic Jacek Zdybski, Ostrowiec Swietokrzyski, Not set
Clinical Research Center Spolka Z Ograniczona Odpowiedzialnoscia Medic-R Spolka Komandytowa, Poznan, Not set
Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W Rzeszowie, Rzeszow, Not set
Mics Centrum Medyczne Toruń, Torun, Not set
High-Med. Przychodnia Specjalistyczna, Warszawa, Not set
Panstwowy Instytut Medyczny Mswia, Warszawa, Not set
Royalderm Agnieszka Nawrocka, Warszawa, Not set
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spolka Partnerska, Wroclaw, Not set
Hospital General Universitario Dr Balmis, Alicante, Not set
Hospital Universitari Germans Trias I Pujol, Badalona, Not set
Hospital de La Santa Creu I Sant Pau, Barcelona, Not set
Hospital Universitario Reina Sofia, Cordoba, Not set
Hospital Clinico Universitario San Cecilio, Granada, Not set
Hospital Universitario Ramon Y Cajal, Madrid, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Universitario La Paz, Madrid, Not set
Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Not set
Hospital de Manises, Manises, Not set
Area Sanitaria de Santiago de Compostela Y Barbanza - Complejo Hospitalario Universitario de Santiag, Santiago de Compostela, Not set
Hospital Universitario Virgen Del Rocio, Seville, Not set
Hospital Universitari I Politecnic La Fe de Valencia - Instituto de Investigacion Sanitaria La Fe, Valencia, Not set
The Dudley Group Nhs Foundation Trust, Dudley, Not set
Ipswich Hospital, East Suffolk and North Essex Nhs Foundation Trust, Ipswich, Not set
Broadgreen Hospital - Liverpool University Hospitals Nhs Foundation Trust, Liverpool, Not set
The Royal London Hospital - Barts Health Nhs Trust, London, Not set
Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust, London, Not set
Poole Hospital - University Hospitals Dorset Nhs Foundation Trust, Poole, Not set
Surrey and Sussex Healthcare Nhs Trust - East Surrey Hospital, Redhill, Not set
Conditions: Prurigo Nodularis
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Recruiting
The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment.
The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/07/2025
Locations: Research Site, Irvine, California +213 locations
Research Site, Irvine, California
Research Site, Aurora, Colorado
Research Site, Denver, Colorado
Research Site, New Haven, Connecticut
Research Site, Washington, District of Columbia
Research Site, Boca Raton, Florida
Research Site, Boynton Beach, Florida
Research Site, Gainesville, Florida
Research Site, Margate, Florida
Research Site, Miami, Florida
Research Site, Orlando, Florida
Research Site, Palm Beach Gardens, Florida
Research Site, Plant City, Florida
Research Site, Atlanta, Georgia
Research Site, Willowbrook, Illinois
Research Site, Fairway, Kansas
Research Site, Baltimore, Maryland
Research Site, Boston, Massachusetts
Research Site, Ann Arbor, Michigan
Research Site, Great Neck, New York
Research Site, Charlotte, North Carolina
Research Site, Charlotte, North Carolina
Research Site, Durham, North Carolina
Research Site, Cleveland, Ohio
Research Site, Middleburg Heights, Ohio
Research Site, Pittsburgh, Pennsylvania
Research Site, Charleston, South Carolina
Research Site, Summerville, South Carolina
Research Site, Allen, Texas
Research Site, Colleyville, Texas
Research Site, El Paso, Texas
Research Site, North Richland Hills, Texas
Research Site, Milwaukee, Wisconsin
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Caba, Not set
Research Site, Quilmes, Not set
Research Site, San Miguel de Tucuman, Not set
Research Site, Camperdown, Not set
Research Site, Nedlands, Not set
Research Site, New Lambton, Not set
Research Site, Southport, Not set
Research Site, Woodville South, Not set
Research Site, Graz, Not set
Research Site, Wien, Not set
Research Site, Gent, Not set
Research Site, Leuven, Not set
Research Site, Merksem, Not set
Research Site, Joinville, Not set
Research Site, Juiz de Fora, Not set
Research Site, Pelotas, Not set
Research Site, Porto Alegre, Not set
Research Site, Salvador, Not set
Research Site, Salvador, Not set
Research Site, Sao Paulo, Not set
Research Site, São José do Rio Preto, Not set
Research Site, Haskovo, Not set
Research Site, Plovdiv, Not set
Research Site, Plovdiv, Not set
Research Site, Sofia, Not set
Research Site, Stara Zagora, Not set
Research Site, Calgary, Alberta
Research Site, Calgary, Alberta
Research Site, Montreal, Quebec
Research Site, Concepcion, Not set
Research Site, Las Condes, Not set
Research Site, Osorno, Not set
Research Site, Santiago, Not set
Research Site, Santiago, Not set
Research Site, Santiago, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Chongqing, Not set
Research Site, Dongguan, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hengyang, Not set
Research Site, Jining, Not set
Research Site, Nanjing, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shijiazhuang, Not set
Research Site, Wenzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Praha 2, Not set
Research Site, Aarhus N, Not set
Research Site, Copenhagen, Not set
Research Site, Odense C, Not set
Research Site, Angers, Not set
Research Site, Brest Cedex 2, Not set
Research Site, Le Mans Cedex, Not set
Research Site, Lille Cedex, Not set
Research Site, Lyon, Not set
Research Site, Paris Cedex 13, Not set
Research Site, Paris, Not set
Research Site, Reims, Not set
Research Site, Rouen, Not set
Research Site, Strasbourg, Not set
Research Site, Toulouse, Not set
Research Site, Bad Nauheim, Not set
Research Site, Berlin, Not set
Research Site, Bonn, Not set
Research Site, Freiburg, Not set
Research Site, Herne, Not set
Research Site, München, Not set
Research Site, Tübingen, Not set
Research Site, Debrecen, Not set
Research Site, Szeged, Not set
Research Site, Ahmedabad, Not set
Research Site, Ahmedabad, Not set
Research Site, Dehradun, Not set
Research Site, Gurugram, Not set
Research Site, Hyderabad, Not set
Research Site, Kolkata, Not set
Research Site, Mumbai, Not set
Research Site, Mumbai, Not set
Research Site, Mumbai, Not set
Research Site, Mysuru, Not set
Research Site, New Delhi, Not set
Research Site, Puducherry, Not set
Research Site, Secunderabad, Not set
Research Site, Afula, Not set
Research Site, Haifa, Not set
Research Site, Jerusalem, Not set
Research Site, Kfar Saba, Not set
Research Site, Ramat Gan, Not set
Research Site, Ancona, Not set
Research Site, Bari, Not set
Research Site, Catania, Not set
Research Site, Milano, Not set
Research Site, Milano, Not set
Research Site, Padova, Not set
Research Site, Palermo, Not set
Research Site, Pavia, Not set
Research Site, Pisa, Not set
Research Site, Roma, Not set
Research Site, Roma, Not set
Research Site, Roma, Not set
Research Site, Rozzano, Not set
Research Site, Siena, Not set
Research Site, Asahikawa-shi, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chiba-shi, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Iruma-Gun, Not set
Research Site, Kawachinagano-shi, Not set
Research Site, Kawasaki-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Omura-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Shinjuku-ku, Not set
Research Site, Tachikawa-shi, Not set
Research Site, Yotsukaido-shi, Not set
Research Site, Daejeon, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Ciudad de Mexico, Not set
Research Site, Culiacan, Not set
Research Site, D.F, Not set
Research Site, Guadalajara, Not set
Research Site, Guadalajara, Not set
Research Site, Mexico City, Not set
Research Site, Mexico, Not set
Research Site, Mexico, Not set
Research Site, Amsterdam, Not set
Research Site, Białystok, Not set
Research Site, Kraków, Not set
Research Site, Kraków, Not set
Research Site, Poznań, Not set
Research Site, Poznań, Not set
Research Site, Warszawa, Not set
Research Site, Warszawa, Not set
Research Site, Wrocław, Not set
Research Site, Łódź, Not set
Research Site, Caguas, Not set
Research Site, San Juan, Not set
Research Site, A Coruña, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Córdoba, Not set
Research Site, L' Hospitalet De Llobregat, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Sabadell, Not set
Research Site, Valladolid, Not set
Research Site, Stockholm, Not set
Research Site, Uppsala, Not set
Research Site, Kaohsiung, Not set
Research Site, Kaohsiung, Not set
Research Site, New Taipei, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Edinburgh, Not set
Research Site, London, Not set
Research Site, Wolverhampton, Not set
Research Site, Ha Noi, Not set
Research Site, Ha Noi, Not set
Research Site, Hanoi City, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh, Not set
Research Site, Hochiminh city, Not set
Research Site, Hue, Not set
Research Site, Hồ Chí Minh, Not set
Conditions: Polymyositis, Dermatomyositis
493 - 504 of 3904